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Warfarin-induced skin necrosis in a patient with protein S deficiency * DOI: http://dx.doi. org/10.1590/abd1806-4841.20187310 Dear Editor, Warfarin-induced cutaneous necrosis is a rare complication of anticoagulant therapy with prevalence between 0.01 and 0.1%, associated to elevated morbimortality. 1 It occurs almost exclusively in patients with venous thrombosis and pulmonary embolism between the 1 st and the 10 th day after initiation of the anticoagulation.
It has been associated to the deficiency of protein C and, more rarely, to the deficiency of protein S. imbalance is exacerbated in protein C or S deficiency, leading to a hypercoagulability state with thrombotic occlusion of the microvasculature, leading to the cutaneous lesions. 3 Most necrotic lesions appear in areas with abundant subcutaneous tissue. The initial lesion is a well-defined, painful erythematous macule that progresses to ecchymosis and then to necrotic tissue. 5 The diagnosis is clinical, and histopathology can be helpful in confirming the diagnosis.
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Once cutaneous necrosis is diagnosed, treatment with heparin should be initiated, along with vitamin K to restore the levels of proteins C and S. The treatment includes discontinuation of warfarin; however, this procedure has not been changing the outcome. 1 Good results are obtained with the cautious reintroduction of low-dose warfarin associated to anticoagulation with heparin. It is essential to know the background for the continuity of the therapy, with dosage of protein C and S, fibrinogen, fibrin degradation products levels and investigation of causes of vasculitis. 3 We highlight that the medical team should be attentive to the subtlest sign or risk factor associated to this syndrome to commence treatment as quickly as possible. Even though it is not usually a life-threatening condition, the inability of early recognition and treatment can lead to sequelae that impair the patients' quality of life. 5 q
